Idarubicin-transarterial chemoembolization combined with gemcitabine plus cisplatin for unresectable intrahepatic cholangiocarcinoma
Idarubicin demonstrated higher cytotoxicity than GemCis, significantly inhibiting tumor growth in tumor-bearing mouse models. Preliminary clinical results suggest that local idarubicin-TACE combined with GemCis may offer improved survival outcomes for iCCA patients with a manageable safety profile.
Authors
- Chenghao Zhao (ORCID: https://orcid.org/0000-0001-5392-7529)
- Junyang Luo (ORCID: https://orcid.org/0000-0002-2665-1608)
- Huzheng Yan (ORCID: https://orcid.org/0000-0002-2196-7734)
- Mingan Li
- Mingsheng Huang (ORCID: https://orcid.org/0000-0003-4749-4231)
- Churen Zhou
- Huan Liu (ORCID: https://orcid.org/0000-0002-0253-647X)
- Mingming Liu (ORCID: https://orcid.org/0000-0002-6750-5068)
- Tao Pan (ORCID: https://orcid.org/0000-0003-3058-2710)
- Luwen Mu (ORCID: https://orcid.org/0000-0003-4967-2214)
- Zhan-Wang Xiang
Institutions
- Sun Yat-sen University (CN)
- Third Affiliated Hospital of Sun Yat-sen University (CN)
Publication Details
- Journal
- World Journal of Gastrointestinal Oncology
- Published
- 2025-03-24
- DOI
- https://doi.org/10.4251/wjgo.v17.i4.103776
- Primary Topic
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00